Drugs / EBVACICLIB
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03519178 | Mar 2018 → Apr 2023 | breast cancer | Pfizer | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBVACICLIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4446357 ↗ |
| Known as | PF-06873600 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03519178 ↗ |
| Modality | Small molecule | — CHEMBL4446357 ↗ |
| Route | Oral | “PF-06873600 tablet for oral dosing” NCT03519178 ↗ |